中
繁
EN
Search form
Search this site
For Patients
Investors
Careers
Contact
Home
About Us
Our Story
Leadership
Board of Directors
Jacobio people stories
Platform & Pipeline
Platform
Pipeline
Publications
Partnership
News
Company News
Media Report
Company News
60
press releases in total
Year
-Year
2024
2023
2022
2021
2020
2019
2018
2024
Jul 26, 2024
Jacobio Completes First Patient Dosage of p53 Y220C Activator
[More]
Jul 15, 2024
Jacobio Appoints Dr. Michael Ren as Vice President of Chemistry
[More]
Jun 13, 2024
Jacobio Appoints Dr. Alan Xiao as Vice President of Clinical Pharmacology
[More]
Jun 2, 2024
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
[More]
May 21, 2024
Jacobio Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for Glecirasib
[More]
May 10, 2024
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of KRAS G12C Inhibitor Glecirasib in Patients with Colorectal Cancer
[More]
May 6, 2024
Jacobio Announces the Submission of New Drug Application for Glecirasib
[More]
May 1, 2024
Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint
[More]
Apr 26, 2024
Jacobio Pharma to Announce Two Oral Presentation at 2024 ASCO
[More]
Apr 17, 2024
Jacobio Receives Orphan Drug Designations for Glecirasib for Pancreatic Cancer in the U.S.
[More]
Apr 9, 2024
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
[More]
Mar 28, 2024
Jacobio Pharma Announces 2023 Annual Results
[More]
Mar 1, 2024
Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30355 in the U.S.
[More]
Feb 18, 2024
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor
[More]
Jan 20, 2024
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI
[More]
2023
Dec 7, 2023
Jacobio Pharma to Present Data of KRAS G12C Inhibitor Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI
[More]
Oct 27, 2023
Jacobio Completes First Patient Dosage of Glecirasib in a Pivotal Clinical Trial for the Treatment of Pancreatic Cancer in China
[More]
Oct 22, 2023
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO
[More]
Aug 30, 2023
Jacobio Pharma Announces 2023 Interim Results
[More]
Aug 7, 2023
Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer
[More]
Pages
1
2
3
›
»
京公网安备 11030102011242号